Daniel P Judge

List of Publications by Citations

196 papers	19,922 citations	67 h-index	140 g-index
216 ext. papers	23,892 ext. citations	8.6 avg, IF	6.42 L-index

#	Paper	IF	Citations
196	Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. *Science*, **2006**, 312, 117-21	33.3	1349
195	A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. *Nature Genetics*, **2005**, 37, 275-81	36.3	1302
194	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. *New England Journal of Medicine*, **2018**, 379, 1007-1016	59.2	859
193	Marfan's syndrome. *Lancet, The*, **2005**, 366, 1965-76	40	813
192	HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Heart Rhythm*, **2011**, 8, 1308-39	6.7	737
191	Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. *New England Journal of Medicine*, **2008**, 358, 2787-95	59.2	633
190	HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Europace*, **2011**, 13, 1077-109	3.9	557
189	Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. *Nature Medicine*, **2007**, 13, 204-10	50.5	535
188	Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. *Journal of the American College of Cardiology*, **2013**, 62, 1290-1297	15.1	413
187	TGF-β-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. *Journal of Clinical Investigation*, **2004**, 114, 1586-1592	15.9	408
186	Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. *Nature*, **2013**, 494, 105-10	50.4	392
185	Arrhythmogenic right ventricular dysplasia: a United States experience. *Circulation*, **2005**, 112, 3823-32	16.7	367
184	Noncanonical TGF-β signaling contributes to aortic aneurysm progression in Marfan syndrome mice. *Science*, **2011**, 332, 358-61	33.3	356
183	Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. *Science*, **2011**, 332, 361-5	33.3	350
182	Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. *European Journal of Heart Failure*, **2012**, 14, 1199-207	12.3	270
181	Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. *Circulation: Cardiovascular Genetics*, **2015**, 8, 437-46		262
180	Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. *Journal of Clinical Investigation*, **2004**, 114, 172-181	15.9	262

179	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm*, **2019**, 16, e301-e372	6.7	247
178	Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. *Circulation*, **2014**, 129, 1092-103	16.7	242
177	Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. *European Heart Journal*, **2015**, 36, 847-55	9.5	238
176	TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. *Journal of Clinical Investigation*, **2004**, 114, 1586-92	15.9	231
175	Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. *Journal of the American College of Cardiology*, **2011**, 57, 2317-27	15.1	216
174	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). *Journal of the American College of Cardiology*, **2016**, 68, 161-72	15.1	215
173	Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Journal of the American College of Cardiology*, **2007**, 50, 432-40	15.1	203
172	KLOTHO allele status and the risk of early-onset occult coronary artery disease. *American Journal of Human Genetics*, **2003**, 72, 1154-61	11	198
171	Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. *Circulation*, **2006**, 113, 1641-9	16.7	194
170	DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. *American Journal of Human Genetics*, **2006**, 79, 136-42	11	190
169	Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, 258-67		179
168	Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. *Journal of the American College of Cardiology*, **2011**, 58, 1485-96	15.1	176
167	Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. *Circulation*, **2015**, 131, 1590-8	16.7	173
166	Mitral valve disease--morphology and mechanisms. *Nature Reviews Cardiology*, **2015**, 12, 689-710	14.8	172
165	Arrhythmogenic Cardiomyopathy. *Circulation Research*, **2017**, 121, 784-802	15.7	167
164	Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). *American Heart Journal*, **2012**, 164, 222-228.e1	4.9	167
163	Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circulation: Cardiovascular Genetics*, **2009**, 2, 428-35		166
162	Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy. *Science Translational Medicine*, **2014**, 6, 240ra74	17.5	165

161	Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. *Journal of Clinical Investigation*, **2004**, 114, 172-81	15.9	165
160	Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. *Journal of Clinical Investigation*, **2014**, 124, 448-60	15.9	164
159	Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome. *Circulation Research*, **2007**, 101, 512-22	15.7	161
158	Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. *Journal of Cardiac Failure*, **2018**, 24, 281-302	3.3	160
157	Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circulation: Arrhythmia and Electrophysiology*, **2012**, 5, 499-505	6.4	156
156	Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. *Heart Failure Reviews*, **2015**, 20, 163-78	5	133
155	Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. *Journal of the American Heart Association*, **2014**, 3, e001471	6	119
154	Genetic testing for dilated cardiomyopathy in clinical practice. *Journal of Cardiac Failure*, **2012**, 18, 296-303	3.3	118
153	Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. *Circulation*, **2017**, 136, e200-e231	16.7	116
152	Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. *Cardiovascular Research*, **2017**, 113, 102-111	9.9	111
151	Mutation-positive arrhythmogenic right ventricular dysplasia/cardiomyopathy: the triangle of dysplasia displaced. *Journal of Cardiovascular Electrophysiology*, **2013**, 24, 1311-20	2.7	110
150	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. *European Heart Journal*, **2020**, 41, 1414-1429	9.5	110
149	Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. *Journal of Cardiovascular Translational Research*, **2013**, 6, 1011-20	3.3	109
148	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. *Journal of the American College of Cardiology*, **2019**, 74, 285-295	15.1	108
147	Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Journal of the American College of Cardiology*, **2006**, 48, 1416-24	15.1	105
146	A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. *European Heart Journal*, **2019**, 40, 1850-1858	9.5	104
145	The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. *Journal of Cardiovascular Magnetic Resonance*, **2012**, 14, 17	6.9	104
144	Short-term effects of right-left heart sequential cardiac resynchronization in patients with heart failure, chronic atrial fibrillation, and atrioventricular nodal block. *Circulation*, **2004**, 110, 3404-10	16.7	104

143	Current treatment of adult Duchenne muscular dystrophy. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2007**, 1772, 229-37	6.9	99
142	Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genetics in Medicine*, **2018**, 20, 899-909	8.1	96
141	Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. *Journal of the American College of Cardiology*, **2013**, 62, 1761-9	15.1	96
140	Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype?. *Human Molecular Genetics*, **2003**, 12, 2269-76	5.6	95
139	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. *Neurology and Therapy*, **2016**, 5, 1-25	4.6	91
138	Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. *Circulation: Heart Failure*, **2015**, 8, 519-26	7.6	90
137	Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Heart Rhythm*, **2015**, 12, 716-25	6.7	85
136	Central role for GSK3□in the pathogenesis of arrhythmogenic cardiomyopathy. *JCI Insight*, **2016**, 1,	9.9	84
135	Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. *Circulation: Arrhythmia and Electrophysiology*, **2013**, 6, 569-78	6.4	82
134	Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. *Circulation: Arrhythmia and Electrophysiology*, **2014**, 7, 230-6	6.4	80
133	Electrocardiographic features of arrhythmogenic right ventricular dysplasia. *Circulation*, **2009**, 120, 477-85	16.7	76
132	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. *Heart Rhythm*, **2019**, 16, e373-e407	6.7	73
131	Yield of serial evaluation in at-risk family members of patients with ARVD/C. *Journal of the American College of Cardiology*, **2014**, 64, 293-301	15.1	69
130	Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 194-204	2.7	68
129	Morphologic variants of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy a genetics-magnetic resonance imaging correlation study. *Journal of the American College of Cardiology*, **2009**, 53, 1289-99	15.1	67
128	The benefit of upgrading chronically right ventricle-paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging. *Heart Rhythm*, **2006**, 3, 435-42	6.7	66
127	Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. *American Journal of Cardiovascular Drugs*, **2011**, 11, 287-94	4	64
126	Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2. *Human Mutation*, **2006**, 27, 1157	4.7	64

125	Neonatal Transplantation Confers Maturation of PSC-Derived Cardiomyocytes Conducive to Modeling Cardiomyopathy. *Cell Reports*, **2017**, 18, 571-582	10.6	63
124	Utility of tissue Doppler and strain echocardiography in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *American Journal of Cardiology*, **2007**, 100, 507-12	3	63
123	Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. *Annals of Neurology*, **2014**, 76, 541-9	9.4	61
122	Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. *Cardiovascular Research*, **2017**, 113, 1521-1531	9.9	58
121	Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. *JACC: Heart Failure*, **2020**, 8, 712-724	7.9	58
120	Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy. *Circulation*, **2019**, 140, 1491-1505	16.7	57
119	Cardiac transplantation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Journal of the American College of Cardiology*, **2012**, 59, 289-90	15.1	57
118	Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *European Heart Journal*, **2016**, 37, 755-63	9.5	56
117	A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. *ELife*, **2015**, 4,	8.9	56
116	Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. *Heart Rhythm*, **2016**, 13, 199-207	6.7	54
115	Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Heart Rhythm*, **2013**, 10, 1661-8	6.7	53
114	Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. *Circulation: Heart Failure*, **2019**, 12, e005371	7.6	51
113	Right ventricular afterload sensitivity dramatically increases after left ventricular assist device implantation: A multi-center hemodynamic analysis. *Journal of Heart and Lung Transplantation*, **2016**, 35, 868-76	5.8	50
112	Mutations in Alstrm protein impair terminal differentiation of cardiomyocytes. *Nature Communications*, **2014**, 5, 3416	17.4	50
111	Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. *Journal of Cardiovascular Translational Research*, **2015**, 8, 117-27	3.3	49
110	Therapy of Marfan syndrome. *Annual Review of Medicine*, **2008**, 59, 43-59	17.4	49
109	Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. *European Journal of Heart Failure*, **2021**, 23, 277-285	12.3	48
108	Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications. *Journal of the American Heart Association*, **2017**, 6,	6	47

107	Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. *European Journal of Heart Failure*, **2019**, 21, 955-964	12.3	47
106	Exercise testing in asymptomatic gene carriers exposes a latent electrical substrate of arrhythmogenic right ventricular cardiomyopathy. *Journal of the American College of Cardiology*, **2013**, 62, 1772-9	15.1	47
105	Relationship between monoclonal gammopathy and cardiac amyloid type. *Cardiovascular Pathology* , **2013**, 22, 189-94	3.8	47
104	Conductance catheter-based assessment of arterial input impedance, arterial function, and ventricular-vascular interaction in mice. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 288, H1157-64	5.2	47
103	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy in the Pediatric Population: Clinical Characterization and Comparison With Adult-Onset Disease. *JACC: Clinical Electrophysiology*, **2015**, 1, 551-560	4.6	46
102	Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. *Annals of Neurology*, **2017**, 82, 44-56	9.4	45
101	Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. *JAMA Cardiology*, **2017**, 2, 1153-1160	16.2	45
100	Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. *Journal of Heart and Lung Transplantation*, **2017**, 36, 380-385	5.8	44
99	Etiology of limb girdle muscular dystrophy 1D/1E determined by laser capture microdissection proteomics. *Annals of Neurology*, **2012**, 71, 141-5	9.4	44
98	Use of genetics in the clinical evaluation of cardiomyopathy. *JAMA - Journal of the American Medical Association*, **2009**, 302, 2471-6	27.4	44
97	Toward an understanding of dural ectasia: a light microscopy study in a murine model of Marfan syndrome. *Spine*, **2005**, 30, 291-3	3.3	41
96	The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus. *European Heart Journal*, **2015**, 36, 872-81	9.5	40
95	Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. *JAMA Cardiology*, **2017**, 2, 293-302	16.2	38
94	Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. *Circulation: Heart Failure*, **2017**, 10,	7.6	38
93	Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. *Heart Rhythm*, **2012**, 9, 961-7	6.7	38
92	Malignant arrhythmogenic right ventricular dysplasia/cardiomyopathy with a normal 12-lead electrocardiogram: a rare but underrecognized clinical entity. *Heart Rhythm*, **2013**, 10, 1484-91	6.7	37
91	Mitral valve disease in Marfan syndrome and related disorders. *Journal of Cardiovascular Translational Research*, **2011**, 4, 741-7	3.3	37
90	Cardiac Management of the Patient With Duchenne Muscular Dystrophy. *Pediatrics*, **2018**, 142, S72-S81	7.4	37

89	Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. *Heart*, **2016**, 102, 303-12	5.1	35
88	Seven factors predict a delayed diagnosis of cardiac amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2018**, 25, 174-179	2.7	35
87	Cardiac phenotype and long-term prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with late presentation. *Heart Rhythm*, **2017**, 14, 883-891	6.7	34
86	Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). *Cardiovascular Drugs and Therapy*, **2020**, 34, 357-370	3.9	34
85	Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. *Circulation*, **2021**, 144, 7-19	16.7	34
84	Nonmyocyte ERK1/2 signaling contributes to load-induced cardiomyopathy in Marfan mice. *JCI Insight*, **2017**, 2,	9.9	33
83	Epidemiology of the inherited cardiomyopathies. *Nature Reviews Cardiology*, **2021**, 18, 22-36	14.8	32
82	A Pkd1-Fbn1 genetic interaction implicates TGF-β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 81-91	12.7	31
81	Variant Interpretation for Dilated Cardiomyopathy: Refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study. *Circulation Genomic and Precision Medicine*, **2020**, 13, e002480	5.2	27
80	The change in B-type natriuretic peptide levels over time predicts significant rejection in cardiac transplant recipients. *Journal of Heart and Lung Transplantation*, **2009**, 28, 704-9	5.8	27
79	Association of common variations on chromosome 4q25 and left atrial volume in patients with atrial fibrillation. *Clinical Medicine Insights: Cardiology*, **2015**, 9, 39-45	3.2	25
78	Comparison of Features of Fatal Versus Nonfatal Cardiac Arrest in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. *American Journal of Cardiology*, **2017**, 120, 111-117	3	24
77	Characterizing the Molecular Pathology of Arrhythmogenic Cardiomyopathy in Patient Buccal Mucosa Cells. *Circulation: Arrhythmia and Electrophysiology*, **2016**, 9, e003688	6.4	24
76	The mitral valve in hypertrophic cardiomyopathy: old versus new concepts. *Journal of Cardiovascular Translational Research*, **2011**, 4, 757-66	3.3	24
75	Prolonged RV endocardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Heart Rhythm*, **2009**, 6, 769-75	6.7	24
74	Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002467	5.2	23
73	Reversible cardiomyopathy caused by administration of interferon alpha. *Nature Clinical Practice Cardiovascular Medicine*, **2005**, 2, 53-7		23
72	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. *Journal of Clinical Investigation*, **2019**, 129, 3171-3184	15.9	23

71	Spectrum of Biventricular Involvement on CMR Among Carriers of ARVD/C-Associated Mutations. *JACC: Cardiovascular Imaging*, **2015**, 8, 863-864	8.4	22
70	Novel and highly lethal NKX2.5 missense mutation in a family with sudden death and ventricular arrhythmia. *Pediatric Cardiology*, **2014**, 35, 1206-12	2.1	22
69	Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction. *Clinical Medicine Insights: Cardiology*, **2014**, 8, 39-44	3.2	22
68	International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003273	5.2	21
67	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational Collaboration. *Circulation: Arrhythmia and Electrophysiology*, **2021**, 14, e008509	6.4	21
66	Familial hypertrophic cardiomyopathy associated with cardiac beta-myosin heavy chain and troponin I mutations. *Pediatric Cardiology*, **2008**, 29, 846-50	2.1	20
65	Genetic evaluation of familial cardiomyopathy. *Journal of Cardiovascular Translational Research*, **2008**, 1, 144-54	3.3	20
64	Shared desmosome gene findings in early and late onset arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Journal of Cardiovascular Translational Research*, **2010**, 3, 663-73	3.3	19
63	Tnni3k alleles influence ventricular mononuclear diploid cardiomyocyte frequency. *PLoS Genetics*, **2019**, 15, e1008354	6	18
62	truncations cause arrhythmogenic right ventricular cardiomyopathy. *Journal of Medical Genetics*, **2020**, 57, 254-257	5.8	17
61	Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes. *Developmental Dynamics*, **2021**, 250, 318-344	2.9	16
60	Lack of Relationship Between Serum Cardiac Troponin I Level and Giant Cell Myocarditis Diagnosis and Outcomes. *Journal of Cardiac Failure*, **2016**, 22, 583-5	3.3	15
59	Exercise triggers CAPN1-mediated AIF truncation, inducing myocyte cell death in arrhythmogenic cardiomyopathy. *Science Translational Medicine*, **2021**, 13,	17.5	15
58	LMNA-associated cardiocutaneous progeria: an inherited autosomal dominant premature aging syndrome with late onset. *American Journal of Medical Genetics, Part A*, **2013**, 161A, 1599-611	2.5	14
57	Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 92-95	2.7	13
56	Multi-scale biomechanical remodeling in aging and genetic mutant murine mitral valve leaflets: insights into Marfan syndrome. *PLoS ONE*, **2012**, 7, e44639	3.7	13
55	Use of a coronary sinus lead and biventricular ICD to correct a sensing abnormality in a patient with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Journal of Cardiovascular Electrophysiology*, **2006**, 17, 317-20	2.7	13
54	Protein molecular modeling techniques investigating novel TAB2 variant R347X causing cardiomyopathy and congenital heart defects in multigenerational family. *Molecular Genetics & Genomic Medicine*, **2018**, 6, 666	2.3	12

53	Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis. *Journal of Cardiovascular Translational Research*, **2015**, 8, 264-8	3.3	11
52	Translational research on the mitral valve: from developmental mechanisms to new therapies. *Journal of Cardiovascular Translational Research*, **2011**, 4, 699-701	3.3	11
51	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. *Circulation*, **2021**, 143, 1852-1862	16.7	11
50	Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy: Case Studies and Proposal for Clinical Surveillance. *Circulation Genomic and Precision Medicine*, **2018**, 11, e002237	5.2	11
49	Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). *Journal of Cardiovascular Electrophysiology*, **2018**, 29, 1004-1009	2.7	10
48	The Role of Genetics in Peripartum Cardiomyopathy. *Journal of Cardiovascular Translational Research*, **2017**, 10, 437-445	3.3	10
47	Characterization of microsatellite markers flanking FBN1: utility in the diagnostic evaluation for Marfan syndrome. *American Journal of Medical Genetics Part A*, **2001**, 99, 39-47		9
46	Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial Biopsy. *Journal of Cardiac Failure*, **2017**, 23, 340-344	3.3	8
45	Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. *Journal of the American Heart Association*, **2020**, 9, e013695	6	8
44	Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. *Circulation: Arrhythmia and Electrophysiology*, **2018**, 11, e005593	6.4	8
43	Comprehensive Versus Targeted Genetic Testing in Children with Hypertrophic Cardiomyopathy. *Pediatric Cardiology*, **2016**, 37, 845-51	2.1	8
42	A family with a complex clinical presentation characterized by arrhythmogenic right ventricular dysplasia/cardiomyopathy and features of branchio-oculo-facial syndrome. *American Journal of Medical Genetics, Part A*, **2013**, 161A, 371-6	2.5	8
41	Cadherin 2-Related Arrhythmogenic Cardiomyopathy: Prevalence and Clinical Features. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003097	5.2	8
40	Reader- and instrument-dependent variability in the electrocardiographic assessment of arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Journal of Cardiovascular Electrophysiology*, **2011**, 22, 561-8	2.7	7
39	Genetic aetiologies should be considered in paediatric cases of acute heart failure presumed to be myocarditis. *Cardiology in the Young*, **2019**, 29, 917-921	1	6
38	Fluctuating creatinine in the cardiac unit. *Clinica Chimica Acta*, **2015**, 447, 52-4	6.2	6
37	Use of genetics in the clinical evaluation and management of heart failure. *Current Treatment Options in Cardiovascular Medicine*, **2010**, 12, 566-77	2.1	6
36	SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. *Heart Lung and Circulation*, **2020**, 29, 1241-1246	1.8	6

35	Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. *American Heart Journal*, **2021**, 233, 122-131	4.9	6
34	Targeted Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve Abnormalities. *Journal of Cardiovascular Development and Disease*, **2015**, 2, 48-65	4.2	5
33	A clinical approach to a family history of sudden death. *Circulation: Cardiovascular Genetics*, **2012**, 5, 697-705		5
32	Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. *Drug Design, Development and Therapy*, **2021**, 15, 1225-1243	4.4	5
31	Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. *ESC Heart Failure*, **2021**, 8, 3875-3884	3.7	5
30	Clinical pathway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 166-167	2.7	4
29	Extensive cardiac allograft vasculitis and concurrent fat necrosis 6 years after orthotopic heart transplantation. *Journal of Heart and Lung Transplantation*, **2007**, 26, 1212-6	5.8	4
28	Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy.. *JAMA - Journal of the American Medical Association*, **2022**, 327, 454-463	27.4	4
27	Review and Updates in Regenerative and Personalized Medicine, Preclinical Animal Models, and Clinical Care in Cardiovascular Medicine. *Journal of Cardiovascular Translational Research*, **2015**, 8, 466-74	3.3	3
26	Advances in induced pluripotent stem cells, genomics, biomarkers, and antiplatelet therapy highlights of the year in JCTR 2013. *Journal of Cardiovascular Translational Research*, **2014**, 7, 518-25	3.3	3
25	Case report of a patient with left ventricular assistance device undergoing chemotherapy for a new diagnosis of lung cancer. *Case Reports in Oncological Medicine*, **2015**, 2015, 163727	0.9	3
24	Familial amyloid cardiomyopathy due to TTR mutations: an underdiagnosed cause of restrictive cardiomyopathy [corrected]. *Journal of Cardiac Failure*, **2009**, 15, 464	3.3	3
23	Arrhythmogenic right ventricular dysplasia/cardiomyopathy: a family affair. *Circulation*, **2011**, 123, 2661-3	36.7	3
22	Phenotypic diversity arising from a single mutation. *Heart Rhythm*, **2009**, 6, 1584-5	6.7	3
21	The prevalent I686T human variant and loss-of-function mutations in the cardiomyocyte-specific kinase gene TNNI3K cause adverse contractility and concentric remodeling in mice. *Human Molecular Genetics*, **2021**, 29, 3504-3515	5.6	3
20	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. *Circulation*, **2021**, 144, 1600-1611	16.7	3
19	ATTR Epidemiology, Genetics, and Prognostic Factors.. *Methodist DeBakey Cardiovascular Journal*, **2022**, 18, 17-26	2.1	3
18	Absence of a Primary Role for SCN10A Mutations in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. *Journal of Cardiovascular Translational Research*, **2016**, 9, 87-9	3.3	2

17	Positive family history decreases diagnosis time by over 200. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **2019**, 26, 17	2.7	2
16	Surgical Correction of Tricuspid Regurgitation in Patients with ARVD/C. *HeartRhythm Case Reports*, **2015**, 1, 326-330	1	2
15	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. *PLoS ONE*, **2018**, 13, e0203078	3.7	2
14	Cardiovascular Disease in Osteogenesis Imperfecta **2014**, 329-334		1
13	Heart failure and genomics. *Journal of the American College of Cardiology*, **2007**, 49, 1106; author reply 1106-7	15.1	1
12	Genetic Dilated Cardiomyopathy Due to TTN Variants Without Known Familial Disease. *Circulation Genomic and Precision Medicine*, **2020**, 13, e003082	5.2	1
11	Influence of Panel Selection on Yield of Clinically Useful Variants in Arrhythmogenic Right Ventricular Cardiomyopathy Families. *Circulation Genomic and Precision Medicine*, **2020**, 13, 548-550	5.2	1
10	Giant Ring Mitochondria in a Patient With Heart Failure and Cerebral White Matter Disease Resulting From an MT-TL1 Mitochondrial Gene Mutation. *Journal of Cardiac Failure*, **2017**, 23, 652-655	3.3	0
9	Wild-Type Transthyretin Cardiac Amyloidosis Is Associated with Increased Antecedent Physical Activity.. *Journal of Cardiovascular Translational Research*, **2022**, 1	3.3	0
8	A pragmatic implementation research study for In Our DNA SC: a protocol to identify multi-level factors that support the implementation of a population-wide genomic screening initiative in diverse populations.. *Implementation Science Communications*, **2022**, 3, 48	2.2	0
7	Translating cardiovascular knowledge: a global health perspective. *Journal of Cardiovascular Translational Research*, **2015**, 8, 1-2	3.3	
6	E713K in desmoglein-2 and arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, E2-E2		
5	Intracardiac giant cells after left ventricular assist device placement. *Journal of Heart and Lung Transplantation*, **2007**, 26, 417-20	5.8	
4	Multivalvular Pulsus Alternans. *Circulation: Heart Failure*, **2020**, 13, e007134	7.6	
3	Cardiac Amyloidosis **2020**, 167-177		
2	Heart Failure as a Consequence of Genetic Cardiomyopathy **2020**, 322-332.e2		
1	Four-Chamber Intracardiac Thrombi Complicating Wild-Type TTR Amyloidosis. *Case Reports in Cardiology*, **2018**, 2018, 1845962	0.6	